MedTrace Logo

Neoadjuvant Atezolizumab in Localized Bladder Cancer

NCT02451423 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-05-31

Study results available
· View outcomes & findings →

Summary

This phase II trial studies the best dose of atezolizumab in treating patients with bladder cancer that has not spread to other places in the body. Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Carcinoma, Transitional Cell

Interventions

DRUG

Atezolizumab

1200 mg Given IV

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Bladder Cancer Advocacy Network

    collaborator OTHER

  • Conquer Cancer Foundation

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • The V Foundation

    collaborator OTHER

  • Lawrence Fong

    lead OTHER

Principal Investigators

  • Lawrence Fong, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-29
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02451423 on ClinicalTrials.gov